Processa Pharmaceuticals (PCSA) Operating Expenses (2012 - 2026)

Processa Pharmaceuticals (PCSA) has reported Operating Expenses for 15 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 36.19% year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $14.1 million (down 0.98% YoY), and the FY2025 full-year result was $16.8 million, up 19.54% from the prior year.
• Operating Expenses fell to $2.9 million in Q2 2026 per PCSA's latest filing, from $4.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $6.1 million in Q3 2022 and bottomed at $2.2 million in Q3 2023.
• Historically, Operating Expenses has averaged $3.7 million across 5 years, with a median of $3.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 97.91% in 2022, then plunged 64.21% in 2023.
• Over 5 years, Operating Expenses stood at $5.8 million in 2022, then plunged by 57.42% to $2.5 million in 2023, then grew by 10.74% to $2.7 million in 2024, then surged by 35.37% to $3.7 million in 2025, then declined by 21.07% to $2.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.9 million, $4.0 million, and $3.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.